REG - Diaceutics PLC - Confirmation of Directorate Change

DiaceuticsAnnouncement

18/03/2022 14:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220318:nRSR3221Fa&default-theme=true

RNS Number : 3221F  Diaceutics PLC  18 March 2022

18 March 2022

Diaceutics PLC

("Diaceutics" or "the Company")

Confirmation of Directorate Change

Further to the Company's announcement on 11 January 2022, Diaceutics confirms
the appointment of Nick Roberts to the Board as Chief Financial Officer
effective today, 18 March 2022.

Accordingly, the Company announces that Philip White has stepped down from the
Board and as Chief Financial Officer.

The Company confirms that there are no additional disclosures required under
the AIM Rules in relation to the appointment of Nick Roberts, further to the
announcement dated 11 January 2022.

 

Enquiries:

 Diaceutics PLC
 Peter Keeling, Chief Executive Officer               Via Alma PR

 Nick Roberts, Chief Financial Officer

 Stifel Nicolaus Europe Limited (Nomad & Broker)      Tel: +44 (0)20 7710 7600
 Ben Maddison, Stewart Wallace, Nick Adams

 Alma PR                                              Tel: +44(0)20 3405 0205
 Caroline Forde, Kieran Breheny, Matthew Young        diaceutics@almapr.co.uk

About Diaceutics

At Diaceutics we believe that every patient should have access to the right
treatment at the right time. We provide the world's leading pharmaceutical
companies with an end-to-end solution for the launch of precision medicine
diagnostics enabled by DXRX - The Diagnostic Network®.

DXRX is the world's first diagnostic commercialisation platform for precision
medicine, integrating multiple pipelines of real-world diagnostic testing data
from a global network of laboratories.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAGPUMUWUPPGCR